ASST Spedali Civili Brescia, Department of Medical Oncology
Welcome,         Profile    Billing    Logout  
 11 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bossi, Paolo
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
I-Tackle, NCT03666325: Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance

Not yet recruiting
2
43
Europe
Pembrolizumab, Keytruda, Cetuximab, Erbitux
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Merck Sharp & Dohme LLC
Skin Neoplasm
10/20
10/22
Dern, NCT03923842 / 2017-005017-31: Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours

Recruiting
2
45
Europe
Denosumab Inj 120 MG/1.7ML, Denosumab treatment, Chemotherapy as clinical standard of care, Standard of care treatment
Gruppo Oncologico del Nord-Ovest, Mario Negri Institute for Pharmacological Research
Nasopharyngeal Carcinoma, EBV Related Carcinoma
09/21
10/22
NEO-CESQ, NCT04632433 / 2019-001469-34: Neoadjuvant Plus Adjuvant Treatment with Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Active, not recruiting
2
25
Europe
Cemiplimab
Fondazione Melanoma Onlus
Cutaneous Squamous Cell Carcinoma
02/23
02/26
PRIME H&N, NCT04681469: Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

Recruiting
2
49
Europe
Niraparib, Dostarlimab
Gruppo Oncologico del Nord-Ovest
Head and Neck Squamous Cell Carcinoma
06/23
06/28
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
IMPEDE, NCT04504552 / 2020-000295-38: Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions

Recruiting
2
240
Europe
Avelumab, Bavencio
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Pfizer S.r.l., AIRC
Oral Premalignant Lesions
10/23
03/24
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
SONIBEC, NCT04806646 / 2020-002613-17: Tailored Sonidegib Schedule After Complete Response in BCC

Recruiting
2
21
Europe
Sonidegib, Odomzo
Gruppo Oncologico del Nord-Ovest
Locally Advanced Basal Cell Carcinoma
01/24
01/26
IntriNSiC, NCT05329792 / 2021-006041-36: L19IL2/L19TNF in Skin Cancer Patients

Recruiting
2
70
Europe
L19IL2/L19TNF, bifikafusp alfa/onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
06/24
12/24
AVEC-119, NCT06869473: Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.

Recruiting
2
67
Europe
Cetuximab/avelumab
Gruppo Oncologico del Nord-Ovest, Merck Serono S.P.A., Italy, Clinical Research Technology S.r.l.
Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
08/27
02/28
POINT, NCT04825990 / 2013-001185-41: Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer

Recruiting
2
30
Europe
Pembrolizumab, olaparib
Gruppo Oncologico del Nord-Ovest
Nasopharyngeal Carcinoma
09/25
03/28
GALAXIES H&N-202, NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck-

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
SupCare, NCT06347185: Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the Study

Not yet recruiting
N/A
160
NA
Early palliative care, integrated with the standard oncologic care (proactive approach), Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)
European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Neoplasms
04/27
12/28
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
HR-cSCC, NCT05246228: Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy

Not yet recruiting
N/A
42
NA
Peripheral blood sampling in order to evaluate changes in the circulating immune population
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Azienda Ospedaliera di Padova, Istituti Ospitalieri di Cremona, IRCCS Sacro Cuore Don Calabria di Negrar, ASST Bergamo Ovest, San Gerardo Hospital, ASST Valcamonica
Squamous Cell Carcinoma of the Skin
11/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bossi, Paolo
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
I-Tackle, NCT03666325: Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance

Not yet recruiting
2
43
Europe
Pembrolizumab, Keytruda, Cetuximab, Erbitux
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Merck Sharp & Dohme LLC
Skin Neoplasm
10/20
10/22
Dern, NCT03923842 / 2017-005017-31: Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours

Recruiting
2
45
Europe
Denosumab Inj 120 MG/1.7ML, Denosumab treatment, Chemotherapy as clinical standard of care, Standard of care treatment
Gruppo Oncologico del Nord-Ovest, Mario Negri Institute for Pharmacological Research
Nasopharyngeal Carcinoma, EBV Related Carcinoma
09/21
10/22
NEO-CESQ, NCT04632433 / 2019-001469-34: Neoadjuvant Plus Adjuvant Treatment with Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Active, not recruiting
2
25
Europe
Cemiplimab
Fondazione Melanoma Onlus
Cutaneous Squamous Cell Carcinoma
02/23
02/26
PRIME H&N, NCT04681469: Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

Recruiting
2
49
Europe
Niraparib, Dostarlimab
Gruppo Oncologico del Nord-Ovest
Head and Neck Squamous Cell Carcinoma
06/23
06/28
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
IMPEDE, NCT04504552 / 2020-000295-38: Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions

Recruiting
2
240
Europe
Avelumab, Bavencio
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Pfizer S.r.l., AIRC
Oral Premalignant Lesions
10/23
03/24
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
SONIBEC, NCT04806646 / 2020-002613-17: Tailored Sonidegib Schedule After Complete Response in BCC

Recruiting
2
21
Europe
Sonidegib, Odomzo
Gruppo Oncologico del Nord-Ovest
Locally Advanced Basal Cell Carcinoma
01/24
01/26
IntriNSiC, NCT05329792 / 2021-006041-36: L19IL2/L19TNF in Skin Cancer Patients

Recruiting
2
70
Europe
L19IL2/L19TNF, bifikafusp alfa/onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
06/24
12/24
AVEC-119, NCT06869473: Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.

Recruiting
2
67
Europe
Cetuximab/avelumab
Gruppo Oncologico del Nord-Ovest, Merck Serono S.P.A., Italy, Clinical Research Technology S.r.l.
Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
08/27
02/28
POINT, NCT04825990 / 2013-001185-41: Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer

Recruiting
2
30
Europe
Pembrolizumab, olaparib
Gruppo Oncologico del Nord-Ovest
Nasopharyngeal Carcinoma
09/25
03/28
GALAXIES H&N-202, NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck-

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
SupCare, NCT06347185: Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the Study

Not yet recruiting
N/A
160
NA
Early palliative care, integrated with the standard oncologic care (proactive approach), Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)
European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Neoplasms
04/27
12/28
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
HR-cSCC, NCT05246228: Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy

Not yet recruiting
N/A
42
NA
Peripheral blood sampling in order to evaluate changes in the circulating immune population
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Azienda Ospedaliera di Padova, Istituti Ospitalieri di Cremona, IRCCS Sacro Cuore Don Calabria di Negrar, ASST Bergamo Ovest, San Gerardo Hospital, ASST Valcamonica
Squamous Cell Carcinoma of the Skin
11/25
12/25

Download Options